Eolo Pharma's New Obesity Drug Promotes Fat Burn Without Appetite Suppression
A new experimental obesity drug called SANA, derived from salicylate, may promote weight loss by increasing energy expenditure through creatine-dependent thermogenesis without suppressing appetite, showing promising results in a small human trial and offering a potential alternative to current GLP-1 based treatments.